Atherosclerosis and inflammation: Overview and updates

Clinical Science

Volumn 132, Issue 12, 2018, Pages 1243-1252

  Geovanini, Glaucylara Reis ^a   Libby, Peter ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ANTIINFLAMMATORY AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HUMAN; INFLAMMATION; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; BLOOD; COMPLICATION; PROCEDURES;

ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; SECONDARY PREVENTION;

EID: 85049519067     PISSN: 01435221     EISSN: 14708736     Source Type: Journal    
DOI: 10.1042/CS20180306     Document Type: Review

References (59)

1. Libby, P. (2012) History of discovery: inflammation in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 32, 2045-2051, https://doi.org/10.1161/ATVBAHA.108.179705
2. Libby, P. (2002) Inflammation in atherosclerosis. Nature 420, 868-874, https://doi.org/10.1038/nature01323
3. Libby, P., Ridker, P.M. and Hansson, G.K. (2009) Inflammation in atherosclerosis: from pathophysiology to practice. J. Am. Coll. Cardiol. 54, 2129-2138, Review, https://doi.org/10.1016/j.jacc.2009.09.009
4. Ridker, P.M. (2016) Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. Eur. Heart J. 37, 1720-1722, Epub 2016 Feb 22. Review, https://doi.org/10.1093/eurheartj/ehw024
5. Libby, P. (2005) The forgotten majority: unfinished business in cardiovascular risk reduction. J. Am. Coll. Cardiol. 46, 1225-1228, https://doi.org/10.1016/j.jacc.2005.07.006
6. Ridker, P.M., Danielson, E., Fonseca, F.A., Genest, J., Gotto, Jr, A.M., Kastelein, J.J. et al. (2009) Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373, 1175-1182, https://doi.org/10.1016/S0140-6736(09)60447-5
7. Bu, D.X., Tarrio, M., Grabie, N., Zhang, Y., Yamazaki, H., Stavrakis, G. et al. (2010) Statin-induced Krüppel-like factor 2 expression in human and mouse T cells reduces inflammatory and pathogenic responses. J. Clin. Invest. 120, 1961-1970, Epub 2010 May 3, https://doi.org/10.1172/JCI41384
8. Yang, L., Zhou, X., Guo, R., Shi, Y., Liang, X. and Heng, X. (2013) Role of Krüppel-like factor 2 and protease-activated receptor-1 in vulnerable plaques of ApoE(-/-) mice and intervention with statin. Can. J. Cardiol. 29, 997-1005, Epub 2013 Feb 5, https://doi.org/10.1016/j.cjca.2012.11.012
9. Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L. et al. (2016) Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388, 2532-2561, https://doi.org/10.1016/S0140-6736(16)31357-5
10. Sacks, F.M., Pfeffer, M.A., Moye, L.A., Rouleau, J.L., Rutherford, J.D., Cole, T.G. et al. (1996) The effectof pravastatin on coronary events after myocardial infarction in patientswith average cholesterol levels. N. Engl. J. Med. 335, 1001-1009, https://doi.org/10.1056/NEJM199610033351401
11. Ridker, P.M., Rifai, N., Pfeffer, M.A., Sacks, F.M., Moye, L.A., Goldman, S. et al. (1998) Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 98, 839-844, https://doi.org/10.1161/01.CIR.98.9.839
12. Ridker, P.M., Cannon, C.P., Morrow, D., Rifai, N., Rose, L.M., McCabe, C.H. et al. (2005) C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 352, 20-28, https://doi.org/10.1056/NEJMoa042378
13. Morrow, D.A., de Lemos, J.A., Sabatine, M.S., Wiviott, S.D., Blazing, M.A., Shui, A. et al. (2006) Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 114, 281-288, https://doi.org/10.1161/CIRCULATIONAHA.106.628909
14. Bohula, E.A., Giugliano, R.P., Cannon, C.P., Zhou, J., Murphy, S.A., White, J.A. et al. (2015) Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of Ezetimibe to Simvastatin and associated with better outcomes in IMPROVE-IT. Circulation 132, 1224-1233, https://doi.org/10.1161/CIRCULATIONAHA.115.018381
15. Cannon, C.P. (2007) High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome. Clin. Cornerstone 8, S14-S23, Review, https://doi.org/10.1016/S1098-3597(07)80011-1
16. Libby, P. and Simon, D.I. (2001) Inflammation and thrombosis: the clot thickens. Circulation 103, 1718-1720, https://doi.org/10.1161/01.CIR.103.13.1718
17. De Caterina, R., D'Ugo, E. and Libby, P. (2016) Inflammation and thrombosis-testing the hypothesis with anti-inflammatory drug trials. Thromb. Haemost 116, 1012-1021, Epub 2016 Aug 18, https://doi.org/10.1160/TH16-03-0246
18. Mason, J.C. and Libby, P. (2015) Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur. Heart J. 36, 482-489c, https://doi.org/10.1093/eurheartj/ehu403
19. Choi, H.K., Rho, Y.H., Zhu, Y., Cea-Soriano, L., Aviña-Zubieta, J.A. and Zhang, Y. (2013) The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study. Ann. Rheum. Dis. 72, 1182-1187, https://doi.org/10.1136/annrheumdis-2012-201669
20. Tan, V.P., Chung, A., Yan, B.P. and Gibson, P.R. (2013) Venous and arterial disease in inflammatory bowel disease. J. Gastroenterol. Hepatol. 28, 1095-1113, https://doi.org/10.1111/jgh.12260
21. Magro, F., Soares, J.B. and Fernandes, D. (2014) Venous thrombosis and prothrombotic factors in inflammatory bowel disease. World J. Gastroenterol. 20, 4857-4872, https://doi.org/10.3748/wjg.v20.i17.4857
22. Naruko, T., Ueda, M., Haze, K., van der Wal, A.C., van der Loos, C.M., Itoh, A. et al. (2002) Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 106, 2894-2900, https://doi.org/10.1161/01.CIR.0000042674.89762.20
23. Ben Chetrit, E. and Levy, M. (1998) Colchicine: 1998 update. Semin. Arthritis Rheum. 28, 48-59, https://doi.org/10.1016/S0049-0172(98)80028-0
24. Nidorf, S.M., Eikelboom, J.W., Budgeon, C.A. and Thompson, P.L. (2013) Low-dose colchicine for secondary prevention of cardiovascular disease. J. Am. Coll. Cardiol. 61, 404-410, https://doi.org/10.1016/j.jacc.2012.10.027
25. Saag, K.G., Teng, G.G., Patkar, N.M., Anuntiyo, J., Finney, C., Curtis, J.R. et al. (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 59, 762-784, https://doi.org/10.1002/art.23721
26. Cronstein, B.N. (2005) Low dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol. Rev. 57, 163-172, https://doi.org/10.1124/pr.57.2.3
27. Hirshberg, B., Muszkat, M., Schlesinger, O. and Rubinow, A. (2000) Safety of low dose methotrexate in elderly patients with rheumatoid arthritis. Postgrad. Med. J. 76, 787-789, https://doi.org/10.1136/pgmj.76.902.787
28. Ridker, P.M. (2009) Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J. Thromb. Haemost 7, 332-339, https://doi.org/10.1111/j.1538-7836.2009.03404.x
29. Everett, B.M., Pradhan, A.D., Solomon, D.H., Paynter, N., Macfadyen, J., Zaharris, E. et al. (2013) Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am. Heart J. 166, 199e15-207e15, https://doi.org/10.1016/j.ahj.2013.03.018
30. Morgan, C.L., Emery, P., Porter, D., Reynolds, A., Young, A., Boyd, H. et al. (2014) Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data. Rheumatology 53, 186-194, https://doi.org/10.1093/rheumatology/ket333
31. Burmester, G.R., Rubbert-Roth, A., Cantagrel, A., Hall, S., Leszczynski, P., Feldman, D. et al. (2014) A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann. Rheum. Dis. 73, 69-74, https://doi.org/10.1136/annrheumdis-2013-203523
32. Ridker, P.M., Everett, B.M., Thuren, T., MacFadyen, J.G., Chang, W.H., Ballantyne, C. et al. (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119-1131, https://doi.org/10.1056/NEJMoa1707914
33. Fearon, W.F. and Fearon, D.T. (2008) Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist. Circulation 117, 2577-2579, https://doi.org/10.1161/CIRCULATIONAHA.108.772491
34. Dinarello, C.A. (2009) Interleukin-1beta and the autoinflammatory diseases. N. Engl. J. Med. 360, 2467-2470, https://doi.org/10.1056/NEJMe0811014
35. Dinarello, C.A. and Wolff, S.M. (1993) The role of interleukin-1 in disease. N. Engl. J. Med. 328, 106-113, https://doi.org/10.1056/NEJM199301143280207
36. Lachmann, H.J., Kone-Paut, I., Kuemmerle-Deschner, J.B., Leslie, K.S., Hachulla, E., Quartier, P. et al. (2009) Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360, 2416-2425, https://doi.org/10.1056/NEJMoa0810787
37. Ruperto, N., Quartier, P., Wulffraat, N., Woo, P., Loy, A., Mouy, A. et al. (2009) A phase II trial with canakinumab (ACZ885), A new IL-1β blocking monoclonal antibody to evaluate the safety and preliminary efficacy in children with systemic juvenile idiopathic arthritis [abstract OP-0298]. Arthritis Rheum. 68, 170-171
38. Ridker, P.M., Howard, C.P., Walter, V., Everett, B., Libby, P., Hensen, J. et al. (2012) Effects of Interleukin-1beta inhibition with canakinumab on hemoglobin a1c, lipids, c-reactive protein, interleukin-6, and fibrinogen: a phase iib randomized placebo controlled trial. Circulation 126, 2739-2748, https://doi.org/10.1161/CIRCULATIONAHA.112.122556
39. Weber, C. and von Hundelshausen, P. (2017) CANTOS Trial validates the inflammatory pathogenesis of atherosclerosis: setting the stage for a new chapter in therapeutic targeting. Circ. Res. 121, 1119-1121, https://doi.org/10.1161/CIRCRESAHA.117.311984
40. Ridker, P.M., MacFadyen, J.G., Everett, B.M., Libby, P., Thuren, T. and Glynn, R.J. (2018) Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet 391, 319-328, https://doi.org/10.1016/S0140-6736(17)32814-3
41. Varbo, A., Benn, M., Tybjærg-Hansen, A. and Nordestgaard, B.G. (2013) Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation 128, 1298-1309, Epub 2013 Aug 7, https://doi.org/10.1161/CIRCULATIONAHA.113.003008
42. Nordestgaard, B.G., Wootton, R. and Lewis, B. (1995) Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo: molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb. Vasc. Biol. 15, 534-542, https://doi.org/10.1161/01.ATV.15.4.534
43. Hovland, A., Aagnes, I., Brekke, O.L., Flage, J.H. and Lappegard, K.T. (2010) No evidence of impaired endothelial function or altered inflammatory state in patients with familial hypercholesterolemia treated with statins. J. Clin. Lipidol. 4, 288-292, https://doi.org/10.1016/j.jacl.2010.02.011
44. Narverud, I., Ueland, T., Nenseter, M.S., Retterstøl, K., Telle-Hansen, V.H., Halvorsen, B. et al. (2011) Children with familial hypercholesterolemia are characterized by an inflammatory imbalance between the tumor necrosis factor a system and interleukin-10. Atherosclerosis 214, 163-168, https://doi.org/10.1016/j.atherosclerosis.2010.10.002
45. Ginsberg, H.N., Elam, M.B., Lovato, L.C., Crouse, III, J.R. and Leiter, L.A. (2010) Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563-1574, https://doi.org/10.1056/NEJMoa1001282
46. d'Emden, M.C., Jenkins, A.J., Li, L., Zannino, D., Mann, K.P., Best, J.D. et al. (2014) Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 57, 2296-2303, Epub 2014 Aug 23, https://doi.org/10.1007/s00125-014-3344-3
47. Bezafibrate Infarction Prevention (BIP) study (2000) Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Bezafibrate infarction prevention (BIP) study. Circulation 102, 21-27, https://doi.org/10.1161/01.CIR.102.1.21
48. Rubins, H.B., Robins, S.J., Collins, D., Fye, C.L., Anderson, J.W., Elam, M.B. et al. (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of highdensity lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341, 410-418, https://doi.org/10.1056/NEJM199908053410604
49. Tavazzi, L., Maggioni, A.P., Marchioli, R., Barlera, S., Franzosi, M.G., Latini, R. et al. (2008) Effect of n-3 polyunsaturated fatty acids in patients with chronicheart failure (the GISSI-HF trial): a randomised, double-blind, placebo controlled trial. Lancet 372, 1223-1230, https://doi.org/10.1016/S0140-6736(08)61239-8
50. Wu, J.H. and Mozaffarian, D. (2014) Omega-3 fatty acids, atherosclerosis progression and cardiovascular outcomes in recent trials: new pieces in a complex puzzle. Heart 100, 530-533, https://doi.org/10.1136/heartjnl-2013-305257
51. Kromhout, D., Giltay, E.J. and Geleijnse, J.M. (2010) n-3 fatty acids and cardiovascular events after myocardial infarction. N. Engl. J. Med. 363, 2015-2026, https://doi.org/10.1056/NEJMoa1003603
52. Rauch, B., Schiele, R., Schneider, S., Diller, F., Victor, N., Gohlke, H. et al. (2010) OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guidelineadjusted therapy after myocardial infarction. Circulation 122, 2152-2159, https://doi.org/10.1161/CIRCULATIONAHA.110.948562
53. Wen, Y.T., Dai, J.H. and Gao, Q. (2014) Effects of Omega-3 fatty acid on major cardiovascular events and mortality in patients with coronary heart disease: a meta-analysis of randomized controlled trials. Nutr. Metab. Cardiovasc. Dis. 24, 470-475, Epub 2013 Dec 25, https://doi.org/10.1016/j.numecd.2013.12.004
54. Aung, T., Halsey, J., Kromhout, D., Gerstein, H.C., Marchioli, R., Tavazzi, L. et al. (2018) Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77917 Individuals. JAMA Cardiol. 3, 225-234, https://doi.org/10.1001/jamacardio.2017.5205
55. Zhang, Y.F., Gao, H.F., Hou, A.J. and Zhou, Y.H. (2014) Effect of omega-3 fatty acid supplementation on cancer incidence, non-vascular death, and total mortality: a meta-analysis of randomized controlled trials. BMC Public Health 14, 204, https://doi.org/10.1186/1471-2458-14-204
56. Bhatt, D.L., Steg, P.G., Brinton, E.A., Jacobson, T.A., Miller, M., Tardif, J.C. et al. (2017) Rationale and design of REDUCE-IT: reduction of cardiovascular events with icosapent ethyl-intervention trial. Clin. Cardiol. 40, 138-148, Epub 2017 Mar 15, https://doi.org/10.1002/clc.22692
57. Bays, H.E., Ballantyne, C.M., Kastelein, J.J., Isaacsohn, J.L., Braeckman, R.A. and Soni, P.N. (2011) Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, Placebo-controlled, Randomized, Double-blind, 12-week study with an open-label Extension [MARINE] trial). Am. J. Cardiol. 108, 682-690, https://doi.org/10.1016/j.amjcard.2011.04.015
58. Ballantyne, C.M., Bays, H.E., Kastelein, J.J., Stein, E., Isaacsohn, J.L., Braeckman, R.A. et al. (2012) Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am. J. Cardiol. 110, 984-992, https://doi.org/10.1016/j.amjcard.2012.05.031
59. Bays, H.E., Ballantyne, C.M., Braeckman, R.A., Stirtan, W.G. and Soni, P.N. (2013) Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am. J. Cardiovasc. Drugs 13, 37-46, https://doi.org/10.1007/s40256-012-0002-3